Related references
Note: Only part of the references are listed.Tim-3 Hampers Tumor Surveillance of Liver-Resident and Conventional NK Cells by Disrupting PI3K Signaling
Siyu Tan et al.
CANCER RESEARCH (2020)
VEGF in Signaling and Disease: Beyond Discovery and Development
Rajendra S. Apte et al.
CELL (2019)
Liver-Resident NK Cells Control Antiviral Activity of Hepatic T Cells via the PD-1-PD-L1 Axis
Jing Zhou et al.
IMMUNITY (2019)
Interleukin-37 monomer is the active form for reducing innate immunity
Elan Z. Eisenmesser et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
The novel role of IL-37 in prostate cancer: evidence as a promising radiosensitizer
Vivi A. Ding et al.
MEDICAL ONCOLOGY (2018)
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Alex M. Abel et al.
FRONTIERS IN IMMUNOLOGY (2018)
IL-37 induces autophagy in hepatocellular carcinoma cells by inhibiting the PI3K/AKT/mTOR pathway
Ting-Ting Li et al.
MOLECULAR IMMUNOLOGY (2017)
被撤回的出版物: Interleukin-37 mediates the antitumor activity in colon cancer through β-catenin suppression (Retracted article. See vol. 10, 2020)
Xiaofei Yan et al.
ONCOTARGET (2017)
Interleukin 37 promotes angiogenesis through TGF-β signaling
Mengmeng Zhao et al.
SCIENTIFIC REPORTS (2017)
Fibronectin: How Its Aberrant Expression in Tumors May Improve Therapeutic Targeting
Jennifer Peyling Wang et al.
JOURNAL OF CANCER (2017)
Homodimerization attenuates the anti-inflammatory activity of interleukin-37
Andrew M. Ellisdon et al.
SCIENCE IMMUNOLOGY (2017)
Suppression of innate inflammation and immunity by interleukin-37
Charles A. Dinarello et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2016)
Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in non-small cell lung cancer
Guanqun Ge et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling
Rui Liu et al.
ONCOTARGET (2016)
Interleukin-37 expression and its potential role in oral leukoplakia and oral squamous cell carcinoma
Lin Lin et al.
SCIENTIFIC REPORTS (2016)
The Low Expression of IL-37 Involved in Multiple Myeloma - Associated Angiogenesis
Zun-chang Li et al.
MEDICAL SCIENCE MONITOR (2016)
Novel endogenous angiogenesis inhibitors and their therapeutic potential
Nithya Rao et al.
ACTA PHARMACOLOGICA SINICA (2015)
Transfer of the IL-37b gene elicits anti-tumor responses in mice bearing 4T1 breast cancer
Wei-qiang Wang et al.
ACTA PHARMACOLOGICA SINICA (2015)
IL-37 Is a Novel Proangiogenic Factor of Developmental and Pathological Angiogenesis
Tianshu Yang et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Manic Fringe Promotes a Claudin-Low Breast Cancer Phenotype through Notch-Mediated PIK3CG Induction
Shubing Zhang et al.
CANCER RESEARCH (2015)
IL-37 mediates the antitumor activity in renal cell carcinoma
Yazhuo Jiang et al.
MEDICAL ONCOLOGY (2015)
IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction
Claudia A. Nold-Petry et al.
NATURE IMMUNOLOGY (2015)
Interleukin 37 Expression Inhibits STAT3 to Suppress the Proliferation and Invasion of Human Cervical Cancer Cells
Sen Wang et al.
JOURNAL OF CANCER (2015)
Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination
I. Sahin et al.
BLOOD CANCER JOURNAL (2014)
Interleukin-37 Mediates the Antitumor Activity in Hepatocellular Carcinoma: Role for CD57+NK Cells
Jing-Jing Zhao et al.
SCIENTIFIC REPORTS (2014)
CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis
Tianxia Jiang et al.
BLOOD (2012)
Matrix metalloproteinase 2 promotes cell growth and invasion in colorectal cancer
Wei Dong et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2011)
Molecular mechanisms and clinical applications of angiogenesis
Peter Carmeliet et al.
NATURE (2011)
Tumor angiogenesis: molecular pathways and therapeutic targets
Sara M. Weis et al.
NATURE MEDICINE (2011)
IL-37 is a fundamental inhibitor of innate immunity
Marcel F. Nold et al.
NATURE IMMUNOLOGY (2010)
CYP1B1 expression promotes the proangiogenic phenotype of endothelium through decreased intracellular oxidative stress and thrombospondin-2 expression
Yixin Tang et al.
BLOOD (2009)
Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production
Yeon-Sook Choi et al.
BLOOD (2009)
Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
Hung Huynh et al.
CLINICAL CANCER RESEARCH (2008)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Effect of vascular normalization, by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: Insights from a mathematical model
Rakesh K. Jain et al.
CANCER RESEARCH (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Fibronectin as target for tumor therapy
M Kaspar et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor β signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model
L Xu et al.
CANCER RESEARCH (2005)
Matrix metalloproteinases and angiogenesis
JE Rundhaug
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2005)
Smoldering and polarized inflammation in the initiation and promotion of malignant disease
F Balkwill et al.
CANCER CELL (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with special reference to activator protein-2, HER2, and prognosis
JM Pellikainen et al.
CLINICAL CANCER RESEARCH (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Platelet factor 4: An inhibitor of angiogenesis
A Bikfalvi
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2004)
The enigmatic role of angiopoietin-1 in tumor angiogenesis
LJ Metheny-Barlow et al.
CELL RESEARCH (2003)
Controlling the angiogenic switch -: A balance between two distinct TGF-β receptor signaling pathways
MJ Goumans et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2003)
IL-1 is required for tumor invasiveness and angiogenesis
E Voronov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity
WT Gao et al.
JOURNAL OF IMMUNOLOGY (2003)
Interleukin-1α (IL-1α) promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion
P Salven et al.
FASEB JOURNAL (2002)
Evidence of IL-18 as a novel angiogenic mediator
CC Park et al.
JOURNAL OF IMMUNOLOGY (2001)
IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk
M Strasly et al.
JOURNAL OF IMMUNOLOGY (2001)
Expression and function of angiopoietin-1 in breast cancer
AJ Hayes et al.
BRITISH JOURNAL OF CANCER (2000)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
Share Paper
